ArticleFrontiers in oncology2026
Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with dismal prognosis for unresectable cases. Systemic chemotherapy shows limited efficacy, while transarterial infusion chemotherapy (HAIC) enables targeted drug delivery, and the combination of anti-angiogenic agents and immune checkpoint inhibitors has demonstrated synergistic effects in solid tumors. Methods: In this retrospective, single-center propensity score-matched study, 183 unresectable PDAC patients treated between January 2021 and December 2024 were analyzed Propensity score matching (PSM) was performed at a 1:1 ratio, resulting in 45 patients in the HAIC + lenvatinib + tislelizumab group and 45 patients in the intravenous chemotherapy group. The primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety. Results: After PSM, baseline characteristics were well-balanced.1). The HAIC + lenvatinib + tislelizumab group achieved significantly higher ORR (37.8% vs. 17.8%, P = 0.023) and DCR (88.9% vs. 64.4%, P = 0.004) than the chemotherapy group. Median OS was 13.1 months (95% CI: 11.4-14.7) in the experimental group versus 8.8 months (95% CI: 7.1-10.9) in the control group (P<0.001). Median PFS was 6.0 months (95% CI: 5.0-6.9) versus 3.7 months (95% CI: 1.9-4.0), respectively (P<0.001). The most common grade ≥3 adverse events were hypertension (15.6% vs. 2.2%, P = 0.012) in the HAIC + lenvatinib + tislelizumab group and neutropenia (24.4% vs. 6.7%, P = 0.008) in the chemotherapy group. Conclusions: HAIC combined with lenvatinib and tislelizumab significantly was associated with significantly prolonged survival and improved tumor response in unresectable PDAC with manageable toxicity, providing a promising therapeutic strategy for this devastating disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.